NEW YORK (GenomeWeb News) – Genewiz today announced a deal with BeiGene for the use of Genewiz's cancer panels to accelerate cancer biomarker discovery.

Under the terms of the deal, Beijing-based BeiGene will use Genewiz's OncoGxOne Discovery cancer panels to identify and elucidate genetic variations in cancers that are prevalent in China and the Asia-Pacific region.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.